Ilse Tack1, Asnake Dumicho2, Liesbet Ohler1, Altynay Shigayeva2, Abera Balcha Bulti1, Kenneth White1, Mduduzi Mbatha3, Jennifer Furin4, Petros Isaakidis5. 1. Medical Department, Médecins sans Frontières, Eshowe, South Africa. 2. Monitoring and Evaluation Department, Médecins sans Frontières, Eshowe, South Africa. 3. King Cetshwayo District TB coordinator, National Department of Health, South Africa. 4. Department of Global Health and Social Medicine, Harvard Medical School, Boston, USA. 5. South African Medical Unit Operational Research Department, Médecins sans Frontières, Cape Town, South Africa.
Abstract
BACKGROUND: At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and two months of linezolid (LZD) for all patients initiating the shorter 9 to 12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal for safety and effectiveness of this treatment regimen under programmatic conditions. METHODS: We conducted a retrospective cohort analysis on RR-TB patients treated with a standardized all-oral short regimen between July 1, 2018 and April 30, 2019 in three facilities in King Cetshwayo District. An electronic register (EDR Web) and facility-based clinical charts were used to collect variables which were entered into an Epi-Info database. RESULTS: Our cohort included 117 patients; 68.4%(95%CI:59.3-76.3) were HIV positive. The median time to culture conversion was 56 days(95%CI:50-57). Treatment success was achieved in 75.2%(95%CI:66.5-82.3) of patients. Mortality within the cohort was 12.8%(95%CI:7.8-20.3). Anaemia was the most frequent severe adverse event. The median time to develop severe anaemia was 7.1 weeks(IQR 4.0-12.9) after treatment initiation. LZD was interrupted in 25.2%(95%CI:17.8-34.5) of participants. CONCLUSIONS: An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. Adverse events (AEs) are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to upskill staff in the monitoring, management and reporting of AEs.
BACKGROUND: At the end of 2018, South Africa updated its all-oral regimen, to include bedaquiline (BDQ) and two months of linezolid (LZD) for all patients initiating the shorter 9 to 12 months regimen for rifampicin-resistant tuberculosis (RR-TB). We assessed a group of patients in rural KwaZulu-Natal for safety and effectiveness of this treatment regimen under programmatic conditions. METHODS: We conducted a retrospective cohort analysis on RR-TB patients treated with a standardized all-oral short regimen between July 1, 2018 and April 30, 2019 in three facilities in King Cetshwayo District. An electronic register (EDR Web) and facility-based clinical charts were used to collect variables which were entered into an Epi-Info database. RESULTS: Our cohort included 117 patients; 68.4%(95%CI:59.3-76.3) were HIV positive. The median time to culture conversion was 56 days(95%CI:50-57). Treatment success was achieved in 75.2%(95%CI:66.5-82.3) of patients. Mortality within the cohort was 12.8%(95%CI:7.8-20.3). Anaemia was the most frequent severe adverse event. The median time to develop severe anaemia was 7.1 weeks(IQR 4.0-12.9) after treatment initiation. LZD was interrupted in 25.2%(95%CI:17.8-34.5) of participants. CONCLUSIONS: An all-oral shorter regimen, including BDQ and LZD as core drugs for the treatment of RR-TB, shows good outcomes, in a high HIV burden rural setting. Adverse events (AEs) are common, especially for LZD, but could be managed in the program setting. Support is needed when introducing new regimens to upskill staff in the monitoring, management and reporting of AEs.
Authors: B Memani; B Beko; N Dumile; E Mohr-Holland; J Daniels; B Sibanda; Z Damse; V Scott; E von der Heyden; C Pfaff; A Reuter; J Furin Journal: Public Health Action Date: 2022-06-21
Authors: Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau Journal: Medicina (Kaunas) Date: 2022-01-26 Impact factor: 2.430
Authors: James C M Brust; Neel R Gandhi; Sean Wasserman; Gary Maartens; Shaheed V Omar; Nazir A Ismail; Angela Campbell; Lindsay Joseph; Alexandria Hahn; Salim Allana; Alfonso C Hernandez-Romieu; Chenshu Zhang; Koleka Mlisana; Charle A Viljoen; Benjamin Zalta; Ismaeel Ebrahim; Meghan Franczek; Iqbal Master; Limpho Ramangoaela; Julian Te Riele; Graeme Meintjes Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079
Authors: Paul E Verweij; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Jochem B Buil; Thierry Calandra; Tom Chiller; Cornelius J Clancy; Oliver A Cornely; Pieter Depuydt; Philipp Koehler; Katrien Lagrou; Dylan de Lange; Cornelia Lass-Flörl; Russell E Lewis; Olivier Lortholary; Peter-Wei Lun Liu; Johan Maertens; M Hong Nguyen; Thomas F Patterson; Bart J A Rijnders; Alejandro Rodriguez; Thomas R Rogers; Jeroen A Schouten; Joost Wauters; Frank L van de Veerdonk; Ignacio Martin-Loeches Journal: Intensive Care Med Date: 2021-06-23 Impact factor: 17.440